Lisa Landrum, MD, PhD

Bio

I am a native of Oklahoma and relocated to Indianapolis in 2021 to serve as the Division Director for Gynecology Oncology at Indiana University School of Medicine. I am a physician-scientist with a clinical and research focus on improving outcomes among people with gynecologic malignancies using novel therapeutic agents through clinical trials. I am board-certified in Obstetrics and Gynecology, Gynecology Oncology and Hospice/Palliative Medicine. Above all, I consider myself an educator and mentor.  I enjoy working alongside students, residents and faculty to provide the best care today and in the future.  

Key Publications

1. Mirza MR, Chase BM, Slomovitz R, dePont Christensen R, Novak Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens E, Zografos E, Coleman RL, Powell MA.  (2023) Dostarlimab for primary advanced or recurrent endometrial cancer.  N Engl J Med. 2023 Mar 27. doi: 10.1056/NEJMoa2216334. PMID: 36972026
2.  Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA, Glen LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O’Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C.  (2023) Pembrolizumab plus chemotherapy in advanced endometrial cancer.  N Engl J Med. 2023 Mar 27. doi: 10.1056/NEJMoa2302312. PMID: 36972022
3. Clarke-Pearson, D.L., Barber, E.L., Landrum, L.M.  American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins – Gynecology. (2021) Prevention of Venous Thromboembolism in Gynecologic Surgery:  ACOG Practice Bulletin, Number 232.  Obstetrics and Gynecology. Jul 1;138(1):e1-e15 PMID 34259490. 
4.  Landrum, L. M., Brady, W. E., Armstrong, D. K., Moore, K., DiSilvestro, P. A., O'Malley, D. M., Tenney, M. E., Rose, P. G., Fracasso, P. M. (2016). A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology, 140(2), 204-9. PMID: 26616225. 
5.  Landrum, L. M., Blank, S., Chen, L. M., Duska, L., Bae-Jump, V., Lee, P. S., Levine, L., McCourt, C., Moore, K., Urban, R. R. (2015). Comprehensive care in gynecologic oncology: The importance of palliative care. Gynecologic oncology, 137(2), 193-202. PMID: 25749723. 
6.  Tewari, K. S., Sill, M. W., Long, 3rd, H. J., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H. E., Monk, B. J. (2014). Improved survival with bevacizumab in advanced cervical cancer. The New England journal of medicine, 370(8), 734-43. PMID: 24552320. 
7. Landrum, L. M., Java, J., Mathews, C. A., Lanneau, Jr, G. S., Copeland, L. J., Armstrong, D. K., Walker, J. L. (2013). Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecologic oncology, 130(1), 12-8. PMID: 23578540.